BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Comment by mbanxon Apr 25, 2011 6:31pm

328 Views

Post# 18485335

RE: 7 cents?

Because "46 Macquarie" broker still on sell side with few millions shares to drop.

As long as they didn't unload everything, the share price will continue to go down, maybe even lower the 52 weeks low.

I'll not buy again over
.05 unless news out.

My only 2 cents.

Bullboard Posts

Shopify stock hits year-high on Q3 results